

NEWS RELEASE

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

2026-08-12

LOS ANGELES--(BUSINESS WIRE)-- **Niagen Bioscience, Inc.** (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the **Midwest IDEAS Investor Conference** on Thursday, August 27, 2026, at The InterContinental Chicago in Chicago, IL.

IDEAS Conferences offer independent regional venues for top-tier companies to present their investment merits to instrumental audiences of investment professionals, offering investor-sponsored events created to benefit regional investment communities.

Niagen Bioscience CFO, Ozan Pamir, will present on Thursday, August 27, from 2:40 - 3:15 PM CT in Presenting Room 2 and be available for one-on-one meetings with institutional investors at the conference. The presentation will be livestreamed and can be accessed through the conference host's main website:

www.threepartadvisors.com/midwest.

If you would like to schedule a one-on-one meeting with the Niagen Bioscience management team during the conference, please contact your respective conference representative or email Niagen@KCSA.com.

For additional information on Niagen Bioscience, visit www.niagenbioscience.com.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing

healthspan through precision science and innovative NAD⁺-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD⁺. A vital coenzyme found in every cell of the human body, NAD⁺ declines with age and exposure to everyday lifestyle stressors. NAD⁺ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age.

At the heart of its clinically proven product portfolio is Niagen[®] (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD⁺ booster available. Niagen powers the Company's consumer supplement, Tru Niagen[®], the number one NAD⁺ boosting oral supplement in the United States[†] (available at www.truniagen.com), and Niagen[™] Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company's wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated molecule.

Niagen Bioscience's robust patent portfolio protects NR and other NAD⁺ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

[†] Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships

310.405.5227

kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:

Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254

Niagen@kcsa.com

Source: Niagen Bioscience, Inc.